Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma

Drummond, 2007, European perspective on the costs and cost-effectiveness of cancer therapies, J Clin Oncol, 25, 191, 10.1200/JCO.2006.07.8956 Sarin, 2008, Criteria for deciding cost-effectiveness for expensive anti-cancer agents, J Cancer Res Ther, 4, 1, 10.4103/0973-1482.39685 Calvo, 2014, Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy, Eur J Cancer, 50, 1321, 10.1016/j.ejca.2014.02.007 Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 Choueiri, 2015, Cabozantinib versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1814, 10.1056/NEJMoa1510016 Choueiri, 2016, Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial, Lancet Oncol, 17, 917, 10.1016/S1470-2045(16)30107-3 Escudier, 2016, Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 27, v58, 10.1093/annonc/mdw328 Cherny, 2017, A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS), Ann Oncol, 28, 2901, 10.1093/annonc/mdw258 Motzer, 2010, Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors, Cancer, 116, 4256, 10.1002/cncr.25219 Rini, 2011, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, Lancet, 378, 1931, 10.1016/S0140-6736(11)61613-9 Hutson, 2014, Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma, J Clin Oncol, 32, 760, 10.1200/JCO.2013.50.3961 Giuliani, 2018, Nivolumab is a cost-effective second-line treatment for metastatic renal-cell carcinoma, Clin Genitourin Cancer, 16, e557, 10.1016/j.clgc.2018.02.006 Swallow, 2018, The additional costs per month of progression-free survival and overall survival: an economic model comparing everolimus with cabozantinib, nivolumab, and axitinib for second-line treatment of metastatic renal cell carcinoma, J Manag Care Spec Pharm, 24, 335 Meng, 2018, Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England, Clinicoecon Outcomes Res, 10, 243, 10.2147/CEOR.S159833 Olchanski, 2015, The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology, Expert Rev Pharmacoecon Outcomes Res, 15, 931, 10.1586/14737167.2015.1102633 Cohn, 2011, At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis, J Clin Oncol, 29, 1247, 10.1200/JCO.2010.32.1075 Shi, 2015, J Clin Oncol, 33, 22, 10.1200/JCO.2014.56.5887 Leung, 2014, Indirect comparisons of efficacy and safety between seven newer targeted agents for metastatic renal cell carcinoma: a network meta-analysis of randomised clinical trials, Mol Clin Oncol, 2, 858, 10.3892/mco.2014.323 Dranitsaris, 2013, Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy, J Cancer Res Clin Oncol, 139, 1917, 10.1007/s00432-013-1510-5 Azimi, 1998, The effectiveness of cost-effectiveness analysis in containing costs, J Gen Intern Med, 13, 664, 10.1046/j.1525-1497.1998.00201.x Hill, 2017, Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis, BMJ Open, 7, e011965, 10.1136/bmjopen-2016-011965 Edwards, 2018, Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation, Health Technol Assess, 22, 1, 10.3310/hta22060 Fishman, 2018, The additional costs per month of progression-free survival and overall survival: an economic model comparing everolimus with cabozantinib, nivolumab, and axitinib for second-line treatment of metastatic renal cell carcinoma, J Manag Care Spec Pharm, 24, 335